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ABSTRACT
CONTEXT AND OBJECTIVE: The relationship between sex hormones and asthma has been evaluated 
in several studies. The aim of this review article was to investigate the association between asthma and 
female sex hormones, under different conditions (premenstrual asthma, use of oral contraceptives, meno-
pause, hormone replacement therapy and pregnancy). 
DESIGN AND SETTING: Narrative review of the medical literature, Universidade Federal do Tocantins (UFT) 
and Universidade Federal de São Paulo (Unifesp). 
METHODS: We searched the CAPES journal portal, a Brazilian platform that provides access to articles in 
the MEDLINE, PubMed, SciELO, and LILACS databases. The following keywords were used based on Medi-
cal Subject Headings: asthma, sex hormones, women and use of oral contraceptives.
RESULTS: The associations between sex hormones and asthma remain obscure. In adults, asthma is more 
common in women than in men. In addition, mortality due to asthma is significantly higher among fe-
males. The immune system is influenced by sex hormones: either because progesterone stimulates pro-
gesterone-induced blocking factor and Th2 cytokines or because contraceptives derived from progester-
one and estrogen stimulate the transcription factor GATA-3. 
CONCLUSIONS: The associations between asthma and female sex hormones remain obscure. We specu-
late that estrogen fluctuations are responsible for asthma exacerbations that occur in women. Because of 
the anti-inflammatory action of estrogen, it decreases TNF-α production, interferon-γ expression and NK 
cell activity. We suggest that further studies that highlight the underlying physiopathological mechanisms 
contributing towards these interactions should be conducted.
RESUMO
CONTEXTO E OBJETIVO: A relação entre os hormônios sexuais e a asma tem sido investigada em diversos 
estudos. Esta revisão tem como objetivo descrever a relação entre hormônios sexuais (endógenos e exó-
genos) e a inflamação nas vias aéreas, especialmente na asma, em eventos diferentes (na asma pré-mens-
trual, durante o uso de anticoncepcionais, na menopausa, no uso de terapia hormonal e na gestação).
TIPO DE ESTUDO E LOCAL: Revisão narrativa da literatura médica, Universidade Federal do Tocantins (UFT) 
e Universidade Federal de São Paulo (Unifesp). 
MÉTODO: Pesquisamos o Portal de Periódicos Capes, uma plataforma brasileira que fornece acesso a 
artigos nas bases de dados MEDLINE, PubMed, SciELO e LILACS. Os descritores utilizados foram asma, hor-
mônios sexuais, mulheres e uso de anticoncepcionais, com base no “Medical Subject Headings”.
RESULTADOS: As associações entre hormônios sexuais e asma ainda permanecem obscuras. Em adultos, 
a asma é mais frequente em mulheres do que em homens. Além disso, a mortalidade por asma é sig-
nificativamente maior no sexo feminino, destacando-se que o sistema imunológico sofre influência de 
hormônios sexuais, seja porque a progesterona estimula o fator bloqueador induzido pela progesterona 
e citocinas Th2 ou porque contraceptivos derivados de progesterona e estrógeno estimulam o fator de 
transcrição GATA-3.
CONCLUSÕES: A associação entre asma e hormônios sexuais femininos permanece obscura. Nós espe-
culamos que as flutuações do estrogênio são responsáveis pelas exacerbações da asma que ocorrem nas 
mulheres. Devido à ação anti-inflamatória do estrogênio há redução da produção de TNF-α, da expressão 
do interferon-γ e da atividade das células NK. Sugerimos que sejam realizados novos estudos para esclare-
cer os mecanismos fisiopatológicos dessas interações.
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INTRODUCTION
Asthma is a heterogeneous process that displays considerable 
phenotypic variability and affects 300 million people globally.1,2 It 
is characterized by the presence of inflammation, hyperrespon-
siveness and reversible airway obstruction. It is considered to be 
a public health problem that affects 21% of the Brazilian popula-
tion.3,4 In Brazil, the mortality rate due to asthma among women 
is 0.241 per 100,000 inhabitants, whereas among men, it is 0.193 
per 100,000 inhabitants.5 Among adults, epidemiological stud-
ies have demonstrated that the prevalence of asthma is higher 
among females than among males.6-8 
The relationship between sex hormones and asthma has been eval-
uated in several studies.9,10 Sex-related differences in the risk, incidence 
and pathogenesis of a variety of lung diseases exist in humans.11 Among 
children, the prevalence is higher in boys than in girls.12 Interestingly, 
after puberty, the frequency and severity of asthma increase among 
girls, such that it becomes more common among women by the age 
of 20 years.13,14 After the menopause, the difference in asthma preva-
lence between men and women decreases.14 Thus, in the United States, 
65% of all deaths due to asthma occur among women.11 
The current paradigm for the pathogenesis of asthma is directly 
related to gene-environment interaction. Production of Th2 cells 
(T helper 2) involves the 5q32 region, which is located on the long 
arm of chromosome 5, in a cluster of genes encoding IL-4 (inter-
leukin 4), IL-5 (interleukin 5), IL-13 (interleukin 13) and IgE 
(immunoglobulin E) levels.15 The transcription factors that relate to 
increased Th2 cytokine levels include STAT-5 (signal transducer and 
activator transducing-5) and GATA-3 (a transcription factor that 
promotes differentiation of Th2 cells from naïve T lymphocytes). 
GATA-3 stimulates growth of Th2 cells and inhibits differentia-
tion to Th1 (T helper 1).16,17 T lymphocytes are important effector 
cells in relation to asthma, and activation of Th2 cells is considered 
to be important, especially in cases of asthma relating to atopy. 
However, immune responses to Th1 lymphocyte activation may be 
responsible for epithelial changes and activation of airway smooth 
muscle. In addition, as the disease becomes chronic, it may cause 
activation of Th1 lymphocytes with increased TNF-α expression 
(tumor necrosis factor) and IFN-γ (interferon gamma). In non-
atopic asthma, a neutrophil inflammatory process may occur.18
Tregs (regulatory T cells) reduce proliferation and decrease 
Th2 levels and hence the inflammatory process in asthma cases.19 
Tregs are essential for induction and maintenance of tolerance 
against antigens.20 In asthmatic patients, Tregs become reduced 
in number and function.20 Recently, other T helper cells were dis-
covered (Th9 and Th17), and these cells are related to the phys-
iopathological process and worsening asthma.21 The role of IL-17 
in asthma is often investigated in patients with non-IgE-mediated 
non-atopic asthma with a predominance of neutrophils, because 
Th17 cell levels correlate with disease severity.22
Sex hormones play an important role in respiratory health, 
and hormone fluctuations may be responsible for exacerbations 
of asthma in women. Hormone fluctuations occur cyclically in 
reproductive-age women. For four days after menstruation, fol-
licle-stimulating hormone (FSH), luteinizing hormne (LH) and 
17-β-estradiol levels are low. During the follicular phase of the 
menstrual cycle (days 12-16), progesterone levels remain low, while 
FSH, LH and 17-β-estradiol levels reach a peak. Finally, during the 
luteal phase (days 24-28 of the cycle), FSH and LH levels are low, 
whereas progesterone and 17-β-estradiol levels are moderately 
high.23 If pregnancy occurs, luteolysis is prevented and the pro-
gesterone and 17-β-estradiol levels remain high. After many years, 
as follicles are depleted and women reaches menopausal status, 
their sex hormone concentrations decrease to very low levels. In 
women using oral contraceptives, the progestin component sup-
presses secretion of LH, and the estrogenic component suppresses 
secretion of FSH, thus preventing ovulation.12 
Asthmatic women need to be monitored for hormonal 
changes.24 In a study conducted by Scichilone that included eight 
healthy women, the progesterone levels during the menstrual cycle 
influenced the concentration of nitric oxide in exhaled air (FeNO) 
and alveolar exhaled nitric oxide (CANO).25 There is evidence sug-
gesting that both endogenous and exogenous sex steroids modu-
late inflammatory processes in the lungs and in smooth muscle 
tissue during different phases of the hormonal cycle in women.26,27
A relationship between sex hormones and inflammatory 
responses in the lower airways, especially with regard to asthma, 
has been observed in several studies.9-14 However, the mechanism 
for this interaction remains obscure. Thus, it is very important to 
review the main findings regarding interactions between sex hor-
mones and to understand the pathophysiological mechanisms of 
this association.
OBJECTIVE
To investigate the association between asthma and female sex 
hormones, at different conditions (premenstrual asthma, use of 
oral contraceptives, menopause, hormone replacement therapy 
and pregnancy). 
METHODS
For this narrative review, we searched for articles that addressed 
association between female sex hormones and asthma regard-
less of clinical situation, which could encompasse premen-
strual period, pregnancy, post-menopause period, use of hor-
mone replacement therapy or oral contraceptives. To do this, we 
searched the journals in the portal of the Coordination Office 
for Improvement of High-Education Personnel (Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior, CAPES). This is 
a Brazilian platform that provides access to bibliographic sources 
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from various locations around the world, including the follow-
ing: MEDLINE, PubMed, SciELO, and LILACS. The follow-
ing keywords were used (based on Medical Subject Headings: 
https://www.nlm.nih.gov/mesh/): asthma and sex hormones (for 
the initial search); and women and oral contraceptives (included 
to refine the analysis). The inclusion criteria were the following: 
complete articles, published over the last 20 years and written 
in English or French. The exclusion criteria were the following: 
items for which the full content was not available, letters to the 
editor, editorials and articles published in non-scientific journals. 
The search was performed in four steps: 
1. Keywords search.
2. Preliminary search to include and exclude articles by using 
their abstracts.
3. Complete articles were read and additional exclusions were made.
4. Synthesis.
RESULTS
Results from search
In the initial search, we identified 447 references. However, 
through the preliminary analysis, only 68 references were 
selected. Only 16 were original articles. The process of study 
selection is presented in a flow diagram (Figure 1). 
Results from studies included
Menstrual cycle and asthma
There is little data about airway physiology and hormonal fluc-
tuations.28 Exacerbation of asthma in the form of premenstrual 
asthma (PMA) affects 30% to 40% of women with asthma.29,30 
PMA was described for the first time by Frank in 1931, who 
reported on a woman who experienced severe attacks of asthma 
that occurred before her menstrual period.31 Some studies have 
reported a decrease in pulmonary function during the premen-
strual portion of the cycle, with a decreased peak expiratory 
flow rate.24 There is also evidence for increased airway inflam-
mation in patients with PMA, as demonstrated by increased lev-
els of eosinophils in sputum and increased levels of fractionated 
exhaled nitric oxide.32 
Tan et al. reported on abnormal regulation of beta2-adreno-
receptors, which was proposed as a possible mechanism for PMA 
during the period of the cycle when progesterone levels are high.33 
The peak incidence of PMA complaints is two to three days before 
the onset of menstruation, but this phenomenon can also occur 
during both the menstrual and premenstrual intervals.31 In a pro-
spective study on 182 female patients with asthma, 46% of all admis-
sions to emergency departments due to acute asthma occurred 
during the perimenstrual period.29,34 Murphy reported that use of 
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Figure 1. Flow diagram showing study selection for review of studies on association between asthma and female sex hormones. 
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oral contraceptives was not protective, and further investigation 
was required to determine the mechanisms involved in PMA.35 
A few studies have described treatments for PMA, with con-
flicting results. Several small series have described use of leukotri-
ene receptor antagonists, exogenous intramuscular progesterone, 
xanthines,14,24 increased doses of inhaled corticosteroids, addition 
of long-acting beta2 agonists during the second half of the men-
strual cycle, oral contraceptives, a single dose of estradiol (2 mg) 
during the luteal phase and gonadotropin-releasing-hormone 
(GnRH) analogues.29 However, more studies are needed in order 
to determine the appropriate treatment for PMA.
Use of hormone contraceptives and asthma
Contraceptives have frequently been used over the last 50 years 
for indications including hirsutism, irregular menstruation, 
dysmenorrhea, polycystic ovarian disease and contraception. 
Recently, clinical evidence has suggested that use of contracep-
tives is associated with impaired lung function.7,36 Some stud-
ies have suggested that use of contraceptives is a risk factor for 
development or exacerbation of asthma crises.7,36 The associa-
tion between asthma and use of combined contraceptives (estro-
gen and progesterone) is unclear. The findings in the literature 
are divergent, given that some studies have reported that estro-
gen and progesterone improve total lung capacity and reduce the 
exacerbation of asthma symptoms, such as coughing, wheez-
ing and dyspnea.37-40 In a study by Carlson et al., use of oral con-
traceptives (combined contraceptives) and unopposed forms of 
estrogens reduced hormone fluctuations and decreased premen-
strual asthma.41 In a study by Lange, no relationship was found 
between use of oral contraceptives and asthma.42 
Erkoçoğlu et al.45 found in a survey on 487 women by means 
of a questionnaire that 196 (40.2%) reported using oral contracep-
tives. This use was associated with higher risk of current wheezing 
among adolescents and young adults, but only among those who 
had taken the oral contraceptives recently during the previous 
year. In a study by Macsali et al.,7 women taking oral contracep-
tives had more asthma and allergies, but this association was not 
present in lean women, and there was an additional association 
with body mass index (BMI). 
The association between asthma, obesity and sex hormones 
has been discussed in the medical literature. Obesity has been 
correlated with higher estrogen levels and with the enzyme aro-
matase, which in adipose tissue can convert androgens into estro-
gens.43,44 The Tucson Children’s Respiratory Study showed a sig-
nificant positive association between obesity and wheezing among 
women who reached puberty when they were under 11 years of 
age, while obesity was not associated with wheezing among women 
in whom puberty occurred after they were 11 years old. In the 
study by Erkoçoğlu et al., there was no evidence of a relationship 
between BMI and current wheezing.45 In a study by Nwaru and 
Sheikh, hormonal contraceptives reduced exacerbation of asthma 
and the number of episodes requiring care. That study also showed 
that overweight and obese women who do not use contraceptives 
may be at higher risk of asthma.38 In a study by Dratva et al., oral 
contraceptives also appeared to have a protective effect, through 
decreasing bronchial hyperreactivity.39 
The cohort study by Jenkins et al. was the first to report an 
association between parity, use of oral contraceptives and the 
onset of asthma among women. In this study, women without 
asthma or wheezing by the age of seven years showed a lower 
risk of developing asthma, and the risk decreased by 7% per 
year of oral contraceptive pill use, independent of parity his-
tory. In this group (women without previous asthma or wheez-
ing), the risk of current asthma increased for each birth (odds 
ratio, OR: 1.50; CI: 1.03-2.23; P = 0.04). Moreover, in the same 
group, the risk of current asthma was greater among women who 
were parous, according to the number of births. Women with 
one birth were at lower risk than nulliparous women. Among 
women who did have asthma or wheezy breathing by the age 
of seven years, neither reproductive history nor oral contracep-
tive pill use predicted current asthma.46
Some authors have suggested mechanisms to explain the 
complex interaction between hormonal contraceptives and 
asthma. Velez-Ortega reported on the impact of oral contra-
ceptives on generation of induced regulatory T cells (iTregs).37 
Dysregulation of iTregs plays a major role in the pathophysiol-
ogy of asthma. In this study, patients taking oral contraceptives 
showed reduced serum sex hormone levels, and this was associ-
ated with higher rates of iTreg induction, better asthma control 
test scores and a tendency towards lower exhaled nitric oxide 
(eNO) levels.37 On the other hand, Guthikonda et al.47 reported 
that oral contraceptives and early menarche (via exogenous or 
endogenous hormones) were associated with the DNA meth-
ylation level of the Th2 transcription factor gene and GATA-3 
and that they increased the risk of asthma among girls, pos-
sibly through interaction with genetic variants. This factor 
may explain how endogenous and exogenous hormones can, 
in women, increase the prevalence of asthma after puberty.47
Another mechanism was reported by Tan et al., who proposed 
that exogenous progesterone but not estradiol induces paradoxi-
cal downregulation and desensitization of β2-adrenoceptors in 
asthmatic women, compared with non-asthmatic subjects.48,49 
Moreover, in another study on eleven women with stable mild to 
moderate asthma, Tan et al. reported that oral contraceptives did 
not alter β2-adrenoceptor regulation and function in stable female 
asthmatic patients.33 
Finally, Salam et al.26 linked oral contraceptive use and 
asthma, both of which are common in young women. The 
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outcomes from their study demonstrated that among women 
without asthma, oral contraceptive use was associated with 
higher risk of current wheezing. In contrast, in the same study, 
oral contraceptive use was associated with reduced prevalence 
of current wheezing among women with asthma. This para-
dox between hormonal contraceptives and immunologically 
unclear characteristics of sex hormones emphasizes the need 
for further research and the importance of knowing a patient’s 
medical history, including the gynecological and hormonal 
characteristics of asthmatic women.26
In Table 1, we have summarized the differences between the 
results from different studies on asthma and hormone contracep-
tives. In Table 2, we have reported the main outcomes from animal 
model studies on sex hormones and asthma.
Postmenopausal hormone replacement 
therapy (HRT) and asthma
Among women over 50 years of age, the menopause can 
either coincide with the onset of asthma or be associated 
with deterioration of a pre-existing asthma condition.50 The 
definition of menopause is the cessation of menstruation 
for 12 months.51 The overall incidence of asthma decreases 
after the menopause,14 although in the Nurses’ Health Study, 
use of hormone replacement therapy (HRT) approximately 
doubled the risk of asthma, compared with postmenopausal 
women without HRT. In that study, a 35% decrease in the 
incidence of asthma was observed among postmenopausal 
women without HRT.10 In a cohort study, Romieu et  al. 
reported that the increase in the risk of asthma onset at the 
Authors Method Results and conclusions
Hellings 
et al.63
BALB/c male mice of 6 weeks of age were sensitized to 
ovalbumin (Ova) using intraperitoneal injections.
Medroxyprogesterone or placebo was instilled daily into 
the esophagus before and during the inhalatory Ova 
challenge phase.
Progesterone worsened allergic airway inflammation in Ova-challenged mice.
Progesterone increased IL-5 levels and elevated airway eosinophilia. 
Progesterone did not influence allergen-specific IgE production.
Progesterone aggravates the phenotype of eosinophilic airway 
inflammation in mice by enhancing systemic IL-5 production.
Degano 
et al.64
Ovariectomized seven-week-old female
Wistar rats received either placebo or 17β-estradiol (E2) (10 
to 100 mcg/kg/day) for 21 days. They were administered 
an aerosol of saline and increasing concentrations of 
acetylcholine (Ach) until lung resistance was observed.
Rats treated with low-dose E2 were less responsive to Ach than rats given 
either placebo or high-dose E2 were.
Treatment with E2 had a differential, dose-dependent effect on airway 
responsiveness to Ach.
de Oliveira 
et al.65
The authors evaluated the roles of estradiol and 
progesterone in allergic lung inflammation. Female Wistar 
rats were ovariectomized (Ovx) and then sensitized with 
ovalbumin (OA). They received estradiol and progesterone.
In Ovx-allergic rats, treatment with estradiol decreased the amount of IL-
10 and increased the amount of IL-4 produced by bone marrow (BM) cells. 
Estradiol increased IL1β and TNFα levels in BAL (bronchoalveolar lavage) 
cells. Progesterone increased the release of IL-10, IL-1β and TNFα by BAL 
cells and increased the production of IL-4 by BM cells.
The existence of such dual hormonal effects suggests that hormone 
therapy in asthmatic postmenopausal women and women who suffer 
from premenstrual asthma should take into account the possibility that 
these treatments may worsen pulmonary conditions.
Mitchell 
et al.66
Adult female BALB/c mice were ovariectomized and 
implanted with time-release progesterone pallets. They 
were housed in filtered air or ETS (environmental tobacco 
smoke) for 6 weeks and exposed to HDMA (house dust mite 
allergen) by inhalation.
Progesterone alone did not increase mucous cell mass or abundance 
of eosinophils, but ETS coupled with progesterone exposure resulted 
in a significant increase in mucous cell metaplasia and increased 
accumulation of eosinophils in the asthma model.
Progesterone, in the absence of estrogen, exacerbated the airway 
inflammation and airway remodeling that was induced by the toxicant ETS.
Matsubara 
et al.67
The authors compared sex differences in the development 
of airway hyperresponsiveness (AHR) following allergen 
exposure exclusively via the airways. Ovalbumin was 
administered via nebulization on 10 consecutive days in 8 to 
10-week male and female BALB/c mice. After methacholine 
challenge, significant AHR developed in male mice but not in 
female mice. Ovariectomized female mice showed significant 
AHR after 10 days of Ova inhalation. ICI182,780, an estrogen 
antagonist, similarly enhanced airway responsiveness even 
when administered 1 hour before the assay.
The results showed that 17 beta-estradiol dose-dependently suppressed 
AHR in male mice. In all cases, airway responsiveness was inhibited by 
administration of a neurokinin 1 receptor antagonist. The neurokinin 
1 receptor antagonist attenuated the effect that the estrogen receptor 
antagonist had in enhancing AHR in female mice in vivo. Endogenous 
estrogen may regulate the neurokinin 1–dependent prejunctional 
activation of airway smooth muscles in allergen-exposed mice.
Table 1. Animal models for sex hormones and airway inflammation
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Authors and 
type of study
Method Results and conclusions
Macsali 
et al.7 
Cross-
sectional 
survey
Postal questionnaires were sent to subjects in 
Denmark, Estonia, Iceland, Norway and Sweden 
from 1999 to 2001 (response rate in women, 
77%). The analyses included 5791 women who 
were 25 to 44 years old, of whom 961 (17%) used 
oral contraceptives.
Oral contraceptive pills were associated with an increased risk of asthma, asthma 
with hay fever, wheezing and shortness of breath, hay fever and ≥ 3 asthma 
symptoms. Associations were present. Women using oral contraceptive pills had 
more asthma. This was found only in the normal weight and overweight women 
and not in lean women, thus indicating an interplay between sex hormones and 
metabolic status in their effects on airways.
Guthikonda 
et al.47 
Cohort
Blood samples were collected from 245 female 
participants aged 18 years old.
Subjects with genotype AG showed an increase in the average risk ratio (RR) from 
0.31 (95% CI: 0.10 to 0.8) to 11.65 (95% CI: 1.71 to 79.5) when the methylation level 
increased from 0.02 to 0.12 relative to the risk in genotype AA. A two-stage model 
that takes into account genetic variants of the GATA-3 gene, oral contraceptive use, 
age at menarche and DNA-methylation may explain how sex hormones can increase 
the prevalence of asthma after puberty.
Erkoçoğlu 
et al.45 
Cross-
sectional
The ISAAC questionnaire was provided to 487 
women between 11.3 and 25.6 years of age. 
Questions on oral contraceptives were also asked.
In this study, n = 487 (ages ranged from 11.3 to 25.6 years old), 196 (40%) reported 
using an oral contraceptive, 7.4% had a diagnosis of asthma from a physician and 
10.3% of them were active smokers. Young women taking oral contraceptives had a 
higher rate of current wheezing, thus suggesting that sex steroids may be important 
for respiratory health.
Dratva 
et al.39
SPALDIA 2
Cohort
571 women aged 28 to 58 years who 
had menstrual periods without hormone 
treatment were subjected to methacholine 
challenge. In a second step, 130 women 
taking oral contraceptives were subjected to 
methacholine challenge.
An effect of modification according to asthma status and oral contraceptive use was 
found, with a lower odds ratio (OR) among subjects without asthma. An OR < 1 was 
found among woman taking oral contraceptives. Oral contraceptives appeared to 
have a protective effect through which they decreased bronchial hyperreactivity. 
Vélez-Ortega 
et al.37 
Cohort
Thirteen patients were included in this pilot 
study. During three distinct phases of their 
menstrual cycles, the authors measured 
exhaled nitric oxide (eNO) levels, forced 
expiratory volume at 1 second (FEV1), asthma 
control test (ACT) scores, sex steroid hormone 
levels in serum, natural Tregs levels in 
peripheral blood, and the ability of CD4+ T cells 
to generate iTregs ex vivo.
Patients taking oral contraceptives showed reduced serum sex hormone levels in 
association with higher levels of iTreg induction, better ACT scores and a tendency 
to have lower eNO levels. The impact of sex hormones on the capacity of T cells to 
polarize towards a regulatory phenotype suggests that regulation of peripheral T cell 
lineage plasticity is a potential mechanism that may underlie the beneficial effects of 
oral contraceptives among women with asthma.
Tan et al.33 
Cohort with 
intragroup 
analysis
The study population comprised 11 women 
aged 19 to 40 years with stable and moderate 
asthma. The patients were evaluated while 
on (day 20 to 21) and off (day 5 to 7) oral 
contraceptives during a 28-day calendar period.
Baseline FEV1
 did not differ between patients who were on and off oral 
contraceptives. These did not alter beta2-adrenoreceptor regulation or function in 
stable female asthmatic patients.
Tan et al.48
Trial
Seven nonsmoking females aged 26 years 
with mild asthma completed the study. They 
were evaluated through two successive 
menstrual cycles during the follicular phase 
(days 1 to 6). They were randomized to receive 
single oral doses of either ethinyl estradiol or 
medroxyprogesterone.
The results showed that exogenous progesterone, but not estrogen, when given 
during the follicular phase, decreased beta2- adrenoreceptor density and cyclic-
adenosine monophosphate (AMP) responses in female asthmatics. The beta2-
adrenoreceptor was abnormally regulated in female asthmatics, and this might be a 
potential mechanism through which premenstrual asthma could be triggered when 
progesterone levels are high.
Salam et al.26
Cohort
905 women who had undergone menarche were 
included. The subjects ranged in age from 13 to 
28 years and had participated in the Children’s 
Health Study.
In women without asthma, oral contraceptive use was associated with higher risk of 
current wheezing. In contrast, oral contraceptive use was associated with reduced 
prevalence of current wheezing in women with asthma. These associations showed 
significant trends with duration of oral contraceptive use.
Age at menarche was associated with new-onset asthma after puberty. Compared with 
women who had their menarche after they were 12 years old, women who reached their 
menarche before they were 12 years old were at higher risk of asthma after puberty.
Because women have a higher risk of asthma after puberty, and because oral 
contraceptive use is common among young women, clinicians should inform 
women with asthma about the potential effects of oral contraceptives on asthma-
related respiratory symptoms.
Table 2. Hormone contraceptives and asthma
Continues...
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Method Results and conclusions
Jenkins 
et al.46
Cohort
681 women aged 29-32 years were randomly 
sampled from participants who were first 
surveyed at the age of 7 years in the 1968 
Tasmanian Asthma Survey, which was a study of 
all children born in 1961 who attended school. 
Current asthma was defined as reporting asthma 
or wheezy breathing during the past 12 months.
The risk of current asthma in individuals who were parous increased with the 
number of births, while women with one birth were at lower risk than nulliparous 
women. Independent of parity, the risk decreased by 7% per year of oral 
contraceptive pill use. In women who had asthma or wheezy breathing by the age 
of 7 years old, neither reproductive history nor oral contraceptive pill use predicted 
current asthma.
Parity and decreased oral contraceptive use predicted asthma in women, and these 
results are consistent with the hypothesis that the asthma that develops after 
childhood is in part a response to endogenous and exogenous female hormones.
Nwaru and 
Sheikh38
Cross-
sectional 
survey
A population-based analysis using serial data 
from the Scottish general population. A total 
of 3257 non- pregnant, 16-45-year-old women 
were included.
The use of any hormonal contraceptive was associated with a reduced risk of current 
physician-diagnosed asthma.
The use of a hormonal contraceptive may reduce asthma exacerbations. Overweight 
and obese non-contraceptive-using women may be at increasing risk of asthma.
Lange et al.42
Cross-
sectional
Data from a study on women who were selected 
from the general population were used to correlate 
the effect of treatment with oral contraceptives 
and hormonal replacement therapy (HRT) with 
asthma indications. 377 women were on oral 
contraceptives (24.5% of the premenopausal 
women) and 458 were on HRT (15.2% of the 
postmenopausal women). The age span of the 
premenopausal women was 21-49 years and of the 
postmenopausal women, 27-90 years.
A weak association was observed between HRT and self-reported asthma.
No relationship was found between the use of oral contraceptives and asthma, 
although an association was observed between asthma and HRT.
Table 2. Continues...
time of the menopause was only significant among women 
who reported using estrogen alone, especially among those 
who had never been smokers and those who had had an 
allergic disease before the onset of asthma. A small increase 
in the risk of asthma among women who used estrogen/pro-
gestogen was found in these subgroups.52 In a systematic 
review and meta-analysis, Zemp et al. found that there was 
no significant association between menopause with asthma 
prevalence or incidence except for women who reported 
using HRT.53 
In a study by Carlson et al., HRT was associated with bet-
ter lung function and an increase in forced expiratory volume at 
one second (FEV1).41 The mechanisms that link asthma and the 
menopause are unclear. After the menopause, FSH and LH levels 
are elevated, and estrogen levels decrease to the levels observed 
in patients with surgical oophorectomy, who also show extremely 
low progesterone levels. The incidence of asthma may be associ-
ated with decreased estrogen levels and a protective effect against 
the relative androgen excess that occurs during the menopausal 
transition.53,54 Clinical studies have indicated that the menopause 
is associated with exacerbation of pre-existing asthma. Thus, the 
onset of asthma is characterized by absence of atopy, absence of 
a family history and associations with urticaria and/or recurrent 
sinusitis of high severity.23 Balzano et al.55 showed that eosinophil 
levels were higher in the induced sputum of menopausal asthmat-
ics, but Foschino Barbaro et al. reported that there were high spu-
tum levels of neutrophils and exhaled interleukin (IL)-6 in women 
with menopausal asthma.50 
Few studies have explored the link between the menopause 
and asthma. Hormonal processes and other factors, including 
genetics and inflammatory and metabolic characteristics, need 
to be taken into consideration. Studies have indicated that obe-
sity has an effect on the severity of asthma and that this relation-
ship is modified by gender. Estrogen and leptin levels (which 
have been correlated with increased airway inflammation in 
animal models)56 are higher in obese women than in non-obese 
women.54 Moreover, obesity has been shown to increase the risk 
of developing asthma. Interestingly, Gómez Real reported that 
lean women presented a higher risk of postmenopausal asthma 
than did obese women using HRT.57 This phenomenon can be 
explained by the notion that in lean women without insulin resis-
tance, the pro-inflammatory effect of estrogens may predominate; 
while in obese women, the pro-inflammatory effects of estrogens 
are decreased through insulin resistance.53
Pregnancy and asthma
Asthma affects 3.7% to 8.4% of all pregnant women in the United 
States. Maternal asthma is associated with an increased risk of both 
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maternal and fetal adverse perinatal outcomes,58 such that 20%-30% 
of women with asthma experience exacerbations that require medi-
cal intervention during pregnancy.43 There is also evidence of an 
increased risk of maternal mortality among some asthmatic women.59 
A number of the physiological changes that occur during preg-
nancy can affect asthma status, including mechanical, immuno-
logical and hormonal alterations. Estradiol and progesterone lev-
els are highest during pregnancy.60 Moreover, one third of women 
experience improved asthma, while another third of women retain 
the same asthma status and the remaining third experience worse 
asthma. Pregnancy is also marked by a state of Th2 dominance, and 
asthma is generally characterized by Th2 inflammation. Progesterone 
receptors are present in large quantities on the surface of lympho-
cytes, and binding of progesterone to its receptor induces stimula-
tion and release of progesterone-induced blocking factor (PIBF) in 
a Th2 cytokine expression pattern (IL-4, IL-5, IL-6, IL-9, IL-10 and 
IL-13). The effects of these proteins are reduced in natural killer 
(NK) cells, in which expression of IFN-γ is decreased. NK cells 
are mainly observed in the endometrium of pregnant women.12,61 
During the first trimester of pregnancy, the numbers of circulating 
and decidual regulatory T cells (Tregs) increase to promote toler-
ance at the maternal-fetal interface.62
Interestingly, fetal sex may influence asthma. Kwon et al. exam-
ined pregnant asthmatic women and found that carrying a female 
fetus was associated with worse maternal asthma than carrying a 
male fetus was.60 The mechanism that contributes towards this 
result is unclear, but there is evidence showing that testosterone 
potentiates the β-adrenergic-mediated relaxation of bronchial tis-
sues and inhibits responses to histamine. Female sex is associated 
with higher maternal circulation of monocytes and upregulation 
of maternal inflammatory pathways.58
The mechanisms through which sex hormones influence asthma 
and the immunological characteristics of pregnancy at the mater-
nal-fetal interface remain obscure, and new studies are needed 
in order to increase our understanding of and ability to manage 
asthmatic women. 
DISCUSSION 
Studies examining the role of hormonal factors in asthma among 
women have been conducted on human subjects and animal 
models, and the results have been described in reviews. In an 
attempt to understand the influence of sex hormones on pulmo-
nary inflammatory responses, we discuss the main immunologi-
cal aspects of sex hormones here.
Studies using animal models have demonstrated that both pro-
gesterone and estrogen can directly affect the lungs.63-67 Sex steroid 
hormones influence the immune system by acting on the struc-
ture and function of the thymus, thereby modulating the activ-
ity of B and T cells, mast cells and natural killer cells (NK cells), 
and affecting phagocytic cells and cytokine production. These 
hormones act via a variety of receptors (including the estrogen 
receptors ERα and ERβ; and the progesterone receptors PR-A and 
PR-B), and these steroid receptors have been described as nuclear 
receptors that act as transcription factors to regulate gene expres-
sion.23 However, it has been shown that some steroid receptors are 
located at the plasma membrane (e.g. membrane-bound G-protein-
coupled receptors).68,69 These receptors are also expressed in the 
human lungs, such that sex hormones play a role in development 
of the lungs and androgen receptors are expressed in the mesen-
chymal and epithelial cells of the lungs. 
Gender differences have been observed in relation to develop-
ment of the lungs. For example, production of surfactants appears 
earlier in female than in male neonatal lungs, and male preterm 
infants are at higher risk of experiencing developmental distress 
syndrome. In addition, before puberty, the prevalence of asthma 
is higher among boys.43 Both male and female fetuses express 
androgen receptors (AR-A, AR-B) in non-reproductive tissues, 
with significantly higher numbers of AR-B than AR-A recep-
tors expressed in the lungs. However, few studies have examined 
expression of androgens in inflammatory airways, and testosterone 
has been shown to cause relaxation of airway smooth muscles.70 
Testosterone may increase apoptosis in T cells, thus resulting in 
a lower percentage of T lymphocytes in the total pool of lympho-
cytes in males than in females.12 
In allergic asthma, airway inflammation is mainly character-
ized by Th2-mediated processes, including secretion of the cyto-
kines IL-4, IL-5, IL-6, IL-9 and IL-13, secretion of chemokines, 
regulation of the activation of normal T cells (RANTES), and 
production of granulocyte macrophage colony-stimulating factor 
(GM-CSF). In patients with asthma and in allergic animal models 
(e.g. allergen-challenged mice), bronchoalveolar lavage contains 
large numbers of eosinophils, M2-polarized macrophages and acti-
vated mast cells. In several cases, the numbers of neutrophils in the 
bronchoalveolar lavage have been found to be higher as a result of 
Th17-mediated responses and production of IL-8.68,69 The airway 
epithelium in asthmatic patients recruits innate and adaptive cells 
via cytokines, including IL-25 and IL-33, and chemokines such as 
CCL2, CCL17 and CCL20, and it secretes transforming growth 
factor beta (TGFβ), which is responsible for airway remodelling.69 
The transition of monocytes along the monocyte-macrophage 
axis is accompanied by upregulation of the 46 kDa ERα.35 Activated 
monocytes and macrophages show increased tumor necrosis fac-
tor-alpha (TNFα) secretion. TNFα is a cytokine produced by Th1 
cells and is an important mediator in pro-inflammatory responses. 
Female reproductive phases also influence the production of TNFα 
by monocytes. In the luteal phase, higher plasma levels of TNFα 
have been observed.12 However, 17β estradiol may decrease TNFα 
levels via an anti-inflammatory effect caused by estrogen.71
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Few studies have examined the effects of sex hormones on 
the bronchial epithelium. The human bronchial epithelium 
expresses both ERα and ERβ. In patients with asthma, estro-
gens facilitate dissociation of endothelial nitric oxide synthetase, 
which results in activation of the NO pathway, vasodilatation 
and increased inflammation.72 In another study, treatment of 
bronchial epithelial cells with 10 nM estrogen induced expres-
sion of NOS and production of nitric oxide, thus resulting in 
bronchodilation.69,73  In a study by Mandhane et al., among 
women who were not using oral contraceptives, an increase in 
progesterone level was associated with an increase in exhaled 
nitric oxide levels, thus indicating that an inflammatory pro-
cess was associated with progesterone.74 
Stimulation of Th2-mediated inflammatory responses and 
asthma by progesterone has been considered by many studies 
to represent a typical Th2 disorder.69,75 In a study by Loza et al., 
increased accumulation of IL-13+T cells (Th2) was observed in 
female but not in male asthmatics, and this association was main-
tained when the analysis was restricted to atopic subjects.75 In an 
animal model, ovariectomized or estradiol antagonist-treated 
mice developed reduced IL-5 dependent eosinophilia during aller-
gic inflammation.76 However, depending on the concentration of 
estrogen, it may play dual pro and anti-inflammatory roles.64,77
CONCLUSIONS
We have attempted to discuss the characteristics that are affected 
by sexual hormones during pulmonary inflammatory responses. 
However, the associations between these factors remain obscure. 
We speculate that estrogen fluctuations are responsible for asthma 
exacerbations that occur in women. Because of the anti-inflam-
matory action of estrogen, as this hormone decreases TNF-α pro-
duction, it reduces IFN-γ expression, and NK cell activity. We 
suggest that further studies that highlight the underlying phys-
iopathological mechanisms contributing towards these interac-
tions should be conducted.
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